X4 Pharmaceuticals (XFOR) Preferred Stock Liabilities (2017 - 2021)

X4 Pharmaceuticals' Preferred Stock Liabilities history runs 3 years deep, the most recent figure standing at $1.9 million for Q2 2021.

• Quarterly Preferred Stock Liabilities changed N/A year-over-year to $1.9 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $1.9 million (changed N/A YoY) and the FY2018 annual result came in at $4.9 million, up 573.98% from the prior year.
• Preferred Stock Liabilities was $1.9 million for Q2 2021 at X4 Pharmaceuticals, roughly flat from $1.9 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $64.7 million in Q3 2018 and bottomed at $734000.0 in Q4 2017.
• A 3-year average of $27.8 million and a median of $4.9 million in 2018 frame the typical range for Preferred Stock Liabilities.
• Peak annual rise in Preferred Stock Liabilities reached 573.98% in 2018, while the deepest fall reached 573.98% in 2018.
• X4 Pharmaceuticals' Preferred Stock Liabilities stood at $734000.0 in 2017, then soared by 573.98% to $4.9 million in 2018, then plunged by 62.1% to $1.9 million in 2021.
• Business Quant data shows XFOR's Preferred Stock Liabilities at $1.9 million in Q2 2021, $1.9 million in Q1 2021, and $4.9 million in Q4 2018.